Cell & Gene The Podcast: Inside BlueRock Therapeutics’ Parkinson’s Disease Trial

Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in the trial, and they also discuss the company’s investigational cell therapy, bemdaneprocel.

Click here to listen.

Related News

Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
Podcasts

Forging the future of cell therapy: Bayer and BlueRock’s unique journey

June 5, 2025
Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
Podcasts

Forging the future of cell therapy: Bayer and BlueRock’s unique journey

June 5, 2025